Login / Signup

Evaluation of prevalence and outcomes of serial tyrosine kinase inhibitor use in pediatric patients with advanced solid tumors.

Hannah E OlsenKevin X LiuA Lindsay FrazierAllison F O'NeillKatherine A JanewaySteven G DuBoisDavid S Shulman
Published in: Pediatric blood & cancer (2023)
We observed a low response rate to mTKI rechallenge. However, we identified patients who had been treated with first mTKI for  ≥4 months as more likely to have prolonged stable disease with second mTKI. Several patients had a response or stable disease on the second mTKI despite having progressed on the first mTKI. Though toxicity was common, only a minority of patients discontinued the second mTKI due to toxicity.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • oxidative stress
  • peritoneal dialysis
  • prognostic factors